Codrituzumab

Cat. No.:	HY-P99013
CAS No.:	1365267-33-9
Target:	Glycoprotein VI
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (K_d of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2][3][4].
In Vitro	Codrituzumab (once-weekly for 21 days) combined with PD-L1 mAb demonstrates a marked antitumor effect, enhancing tumor infiltration of PD-L1-positive immune cells, such as macrophages and multinucleated giant cells in the Hepa1-6/hGPC3 mice model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Small Sci. 2024 Nov 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.

[2]. Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20.

[3]. Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444.

[4]. Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA